These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29043996)

  • 41. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
    Tang SY; Peng DF; Hu YJ; Chen J
    Eur Rev Med Pharmacol Sci; 2015; 19(5):759-66. PubMed ID: 25807427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and risk factors for pulmonary arterial hypertension in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis.
    Zhang L; Zhao S; Ma J; Gong J; Qiu G; Ren Y; Zen Y; Shi Y
    Ren Fail; 2016 Jun; 38(5):815-21. PubMed ID: 26888091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of recombinant human brain natriuretic peptide on emergency dialysis and prognosis in end-stage renal disease patients with type 4 cardiorenal syndrome.
    Zhou Y; Wang X; Yuan H; Wu L; Zhang B; Chen X; Zhang Y
    Sci Rep; 2023 Nov; 13(1):20752. PubMed ID: 38007545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure.
    Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Verdiani V; Tijssen JG; Pinto YM
    JACC Heart Fail; 2015 Oct; 3(10):751-61. PubMed ID: 26449995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects].
    Wu YR; Chen SB; Huang MR; Zhang YQ; Sun K; Chen S
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):161-4. PubMed ID: 15833183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
    Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
    Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP).
    Mueller T; Gegenhuber A; Poelz W; Haltmayer M
    Clin Chem Lab Med; 2004 Feb; 42(2):159-63. PubMed ID: 15061354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective effects of recombinant human brain natriuretic peptide in perioperative period during open heart surgery.
    Xu Y; Li Y; Bao W; Qiu S
    Exp Ther Med; 2018 Mar; 15(3):2869-2873. PubMed ID: 29456690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effects of recombinant human brain natriuretic peptide and milrinone on cardiac hemodynamics and renal function in anesthetized dog].
    Xu XW; Yang W; Zhao ZY; Liu HX; Zeng GY
    Yao Xue Xue Bao; 2002 Jul; 37(7):506-9. PubMed ID: 12914318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy.
    Kaufmann BA; Goetschalckx K; Min SY; Maeder MT; Bucher U; Nietlispach F; Bernheim AM; Pfisterer ME; Brunner-La Rocca HP;
    Int J Cardiol; 2015 Jul; 191():286-93. PubMed ID: 25981371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population.
    Groenning BA; Raymond I; Hildebrandt PR; Nilsson JC; Baumann M; Pedersen F
    Heart; 2004 Mar; 90(3):297-303. PubMed ID: 14966052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-terminal-probrain natriuretic peptide and echocardiography in patients with systolic heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Saudi Med J; 2005 Nov; 26(11):1695-8. PubMed ID: 16311650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orthostatic hypotension of unknown cause: Unanticipated association with elevated circulating N-terminal brain natriuretic peptide (NT-proBNP).
    Krishnan B; Patarroyo-Aponte M; Duprez D; Pritzker M; Missov E; Benditt DG
    Heart Rhythm; 2015 Jun; 12(6):1287-94. PubMed ID: 25684232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.